Noha Salama
Associate Professor, Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University
(email)
Buparlisib. Phosphatidylinositol 3-kinase alpha inhibitor, Oncolytic.
View
What links here
Citation:
Azab, F., B. Muz, P. de la Puente, and A. - K. Salama, N and Azab, "Buparlisib. Phosphatidylinositol 3-kinase alpha inhibitor, Oncolytic.", Drugs of the Future , vol. 38, issue 2, pp. 73-79, 2013.
Export
RTF
Tagged
XML
BibTex
Google Scholar
Preview
Attachment
Size
noha_nabi_salama-__2013.pdf
144.26 KB
Publications
Bio
Classes
Calendar
Recent Publications
Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis.
Targeting E-selectin to Tackle Cancer Using Uproleselan
Targeting CD47 as a Novel Immunotherapy for Multiple Myeloma.
Tumor microenvironment-targeted nanoparticles loaded with bortezomib and ROCK inhibitor improve efficacy in multiple myeloma.
Palbociclib and cetuximab in platinum-resistant and in cetuximab-resistant human papillomavirus-unrelated head and neck cancer: a multicentre, multigroup, phase 2 trial.
more
Tourism